Compound and lipid composition
By using sterol derivatives of specific structures and other lipid combinations in the lipid composition, the problem of low nucleic acid delivery efficiency in the prior art is solved, and efficient nucleic acid cell introduction is achieved.
Patent Information
- Application Number
- CN202380027610.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-15
- Filing Date
- 2023-03-14
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to achieve excellent nucleic acid delivery efficiency, especially when steroid compounds different from cholesterol are used, the transfection efficiency is low.
Using sterol derivatives of a specific structure, such as the compound represented by formula (1), as sterol components in the lipid composition, combine with ionizable lipids, neutral lipids and nonionic hydrophilic polymers. The combination of the product forms an excellent nucleic acid delivery vector.
The cell introduction efficiency of nucleic acids is significantly improved and the excellent nucleic acid delivery effect is achieved.
Smart Images

Figure CN118984831A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a sterol compound and a lipid composition comprising the sterol compound. Background Art
[0002] Nucleic acid drugs have a clear mechanism of action on diseases and few side effects. They are expected to be the next generation of pharmaceuticals, and the development of nucleic acid drugs is being actively carried out. As one of the technologies for delivering nucleic acids to cells, there is a method of administering nucleic acids by including nucleic acids in liposomes or lipid particles. In this technology, lipids are used, and the delivery of nucleic acids is achieved by giving appropriate charges to the particles.
[0003] For example, Patent Document 1 describes a lipid composition comprising an amino lipid having a specific structure, a nonionic lipid, a lipid having a nonionic hydrophilic polymer structure, and a nucleic acid. Patent Document 2 describes a lipid composition comprising an amino lipid having a specific structure, sterols, and nucleic acids, and the molar ratio of the amino lipid to the sterols is greater than 0.300 and less than 1.299.
[0004] The lipid composition for nucleic acid delivery is mainly composed of amino lipids, neutral lipids, cholesterol, and lipids with nonionic hydrophilic polymer structures. In recent years, reports have been made that the transfection efficiency is improved by changing cholesterol to other sterols (patent document 3 and non-patent document 1). For example, focusing on cholate in sterols, cholate substituted by chain alkyl is known (patent document 3), and it has been clearly shown that cholate substituted by cyclic alkyl and aryl shows higher transfection efficiency.
[0005] Prior art literature
[0006] Patent Literature
[0007] Patent Document 1: International Publication No. WO2020 / 246581
[0008] Patent Document 2: International Publication No. WO2021 / 095876
[0009] Patent Document 3: International Publication No. WO2020 / 061332
[0010] Non-patent literature
[0011] Non-patent document 1: NATURE COMMUNICATIONS (2020) 11:983 Summary of the invention
[0012] Technical issues to be solved by the invention
[0013] Still expect to achieve excellent nucleic acid delivery efficiency of the development of lipid compositions. The problem that the present invention should solve is to provide a sterol compound that can achieve excellent nucleic acid delivery efficiency when used in a lipid composition. The problem that the present invention should solve is also to provide a lipid composition, which comprises the above-mentioned sterol compound and can achieve excellent nucleic acid delivery efficiency.
[0014] Means for solving technical problems
[0015] As a result of in-depth research conducted by the inventors to solve the above-mentioned problems, it was found that by using the compound represented by the formula (1) described later as a sterol derivative in a lipid composition, a lipid composition showing excellent nucleic acid delivery efficiency can be obtained. The present invention is completed based on the above-mentioned discovery. According to the present invention, the following invention can be provided.
[0016] <1> A compound represented by formula (1),
[0017] [Chemical formula 1]
[0018]
[0019] In the formula,
[0020] [Chemical formula 2]
[0021]
[0022] represents a single bond or a double bond,
[0023] R 201 represents a cyclic hydrocarbon group which may be substituted with one or more substituents, wherein the substituents are hydrocarbon groups having 1 to 18 carbon atoms,
[0024] R 102 express
[0025] (i) Hydrogen atoms,
[0026] (ii) may be selected from OH, SH, COOH, NR 106 R 107 、N(R 108 )C(O)R 109 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents,
[0027] (iii)C(O)R 103 or
[0028] (iv)C(O)NR 104 R 105 ,
[0029] R 103It can be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents in
[0030] R 104 and R 105 Each independently represents a hydrogen atom, or may be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents in
[0031] R 106 , R 107 , R 108 and R 109 Each independently represents a hydrogen atom, or may be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents in
[0032] R 110 , R 111 , R 112 and R 113 Each independently represents a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms which may be substituted with one or more substituents selected from OH and SH.
[0033] <2> The compound according to <1>, wherein
[0034] R 102 represents (i) a hydrogen atom or (iv) C(O)NR 104 R 105 .
[0035] <3> The compound according to <1> or <2>, which is a compound represented by formula (1A).
[0036] [Chemical formula 3]
[0037]
[0038] In the formula, R 201 As described in <1>.
[0039] <4> The compound according to any one of <1> to <3>, wherein
[0040] The cyclic hydrocarbon group is an aliphatic cyclic hydrocarbon group.
[0041] <5> The compound according to <4>, wherein
[0042] The aliphatic cyclic hydrocarbon group is a monocyclic hydrocarbon group.
[0043] <6> The compound according to <5>, wherein
[0044] The monocyclic hydrocarbon group has 3 to 18 carbon atoms.
[0045] <7> The compound according to <4>, wherein
[0046] The aliphatic cyclic hydrocarbon group is a bicyclic hydrocarbon group.
[0047] <8> The compound according to <7>, wherein
[0048] The bicyclic hydrocarbon group has 4 to 18 carbon atoms.
[0049] <9> The compound according to <4>, wherein
[0050] The aliphatic cyclic hydrocarbon group is a tricyclic hydrocarbon group.
[0051] <10> The compound according to <9>, wherein
[0052] The tricyclic hydrocarbon group has 5 to 18 carbon atoms.
[0053] <11> The compound according to any one of <1> to <3>, wherein
[0054] The cyclic hydrocarbon group is an aromatic hydrocarbon group.
[0055] <12> The compound according to <11>, wherein
[0056] The aromatic hydrocarbon group has 6 to 10 carbon atoms.
[0057] <13> The compound according to any one of <1> to <12>, wherein
[0058] R 201 The substituent on the cyclic hydrocarbon group in the definition of is a hydrocarbon group having 1 to 18 carbon atoms.
[0059] <14> The compound according to any one of <1> to <13>, wherein
[0060] R 201 The substituent on the cyclic hydrocarbon group in the definition of is a hydrocarbon group having 1 to 8 carbon atoms.
[0061] <15> A lipid composition comprising the compound according to any one of <1> to <14> and at least one lipid.
[0062] <16> The lipid composition according to <15>, further comprising a nucleic acid.
[0063] <17> The lipid composition according to <15> or <16>, further comprising a pharmaceutically acceptable carrier.
[0064] <18> The lipid composition according to any one of <15> to <17>, which is a composition for introducing a nucleic acid into a cell.
[0065] <19> The lipid composition according to any one of <15> to <17>, which is a composition for in vivo nucleic acid delivery.
[0066] <20> The lipid composition according to any one of <15> to <19>, which is a lipid particle.
[0067] Effects of the Invention
[0068] The compound of the present invention can achieve excellent nucleic acid delivery efficiency by being used in a lipid composition. DETAILED DESCRIPTION
[0069] Hereinafter, the present invention will be described in detail.
[0070] In this specification, "to" represents a range including the numerical values described before and after it as the minimum value and the maximum value, respectively.
[0071] <Compound represented by formula (1)>
[0072] The compound of the present invention is a compound represented by the following formula (1).
[0073] [Chemical formula 4]
[0074]
[0075] In the formula,
[0076] [Chemical formula 5]
[0077]
[0078] represents a single bond or a double bond,
[0079] R 201 represents a cyclic hydrocarbon group which may be substituted with one or more substituents, wherein the substituents are hydrocarbon groups having 1 to 18 carbon atoms,
[0080] R102 express
[0081] (i) Hydrogen atoms,
[0082] (ii) may be selected from OH, SH, COOH, NR 106 R 107 、N(R 108 )C(O)R 109 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents,
[0083] (iii)C(O)R 103 or
[0084] (iv)C(O)NR 104 R 105 ,
[0085] R 103 It can be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents in
[0086] R 104 and R 105 Each independently represents a hydrogen atom, or may be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents in
[0087] R 106 , R 107 , R 108 and R 109 Each independently represents a hydrogen atom, or may be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents in
[0088] R 110 , R 111 , R 112 and R 113Each independently represents a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms which may be substituted with one or more substituents selected from OH and SH.
[0089] The hydrocarbon group having 1 to 18 carbon atoms in the definition of formula (1) is a monovalent or divalent hydrocarbon group, and may be linear or branched. The hydrocarbon group having 1 to 18 carbon atoms preferably has 1 to 12 carbon atoms, and more preferably has 1 to 6 carbon atoms.
[0090] The hydrocarbon group having 1 to 4 carbon atoms in the definition of formula (1) may be any of a saturated hydrocarbon group and an unsaturated hydrocarbon group, and may be any of a straight chain or a branched chain, but is preferably a saturated hydrocarbon group. Examples of the hydrocarbon group having 1 to 4 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, and the like.
[0091] R 201 It represents a cyclic hydrocarbon group which may be substituted with one or more substituents, wherein the substituent is a hydrocarbon group having 1 to 18 carbon atoms.
[0092] The cyclic hydrocarbon group refers to a group having one or more saturated or unsaturated carbon rings.
[0093] As R 201 The cyclic hydrocarbon group in the definition of may be any of an aliphatic cyclic hydrocarbon group and an aromatic hydrocarbon group.
[0094] The number of rings in the aliphatic cyclic hydrocarbon group is not particularly limited, but the aliphatic cyclic hydrocarbon group is preferably a monocyclic hydrocarbon group, a bicyclic hydrocarbon group or a tricyclic hydrocarbon group, and is particularly preferably a monocyclic hydrocarbon group.
[0095] The monocyclic hydrocarbon group has preferably 3 to 18 carbon atoms, more preferably 3 to 12 carbon atoms, further preferably 6 to 12 carbon atoms, for example 6 carbon atoms.
[0096] The bicyclic hydrocarbon group preferably has 4 to 18 carbon atoms, more preferably 4 to 12 carbon atoms, further preferably 7 or 8 carbon atoms, for example 7 carbon atoms.
[0097] The tricyclic hydrocarbon group has preferably 5 to 18 carbon atoms, more preferably 6 to 16 carbon atoms, further preferably 6 to 12 carbon atoms, for example 10 carbon atoms.
[0098] The number of carbon atoms in the aromatic hydrocarbon group is preferably 6 to 10, more preferably 6 to 8, for example 6.
[0099] R 201 The substituent on the cyclic hydrocarbon group in the definition of is preferably a hydrocarbon group having 1 to 8 carbon atoms (for example, methyl, ethyl, isopropyl, n-propyl, etc.).
[0100] Preferably, in formula (1), R102 express
[0101] (i) Hydrogen atom or
[0102] (iv)C(O)NR 104 R 105 .
[0103] More preferably, in formula (1), R 102 Represents a hydrogen atom.
[0104] Preferred R 104 and R 105 Each independently represents a hydrogen atom, or may be selected from OH, SH, N(R 112 )C(O)R 113 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents.
[0105] More preferably, R 104 and R 105 Each independently represents a hydrogen atom, or may be selected from OH, N(R 112 )C(O)R 113 or CF 3 A hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents.
[0106] More preferably, R 104 and R 105 Each independently represents a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms which may be substituted with OH.
[0107] Preferably, R 110 , R 111 , R 112 and R 113 Each independently represents a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms which may be substituted with one or more OH groups.
[0108] Preferably,
[0109] [Chemical formula 6]
[0110]
[0111] Represents a double bond.
[0112] Preferably, the compound of the present invention is a compound represented by formula (1A).
[0113] [Chemical formula 7]
[0114]
[0115] In the formula, R 201As described above in this specification.
[0116] In particular, it is preferred that the compound represented by formula (1) is the following compounds 1 to 10 described in Examples 1 to 10 described later.
[0117] (1S,4S)-4-(tert-butyl)cyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 1);
[0118] (1R,4R)-4-(tert-butyl)cyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 2);
[0119] (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 3);
[0120] (1S,2S,5R)-2-isopropyl-5-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 4);
[0121] Cyclooctyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 5);
[0122] Cyclododecyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 6);
[0123] (2R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl (4R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 7);
[0124] 1,3,3-Trimethylbicyclo[2.2.1]heptan-2-yl (4R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 8);
[0125] (1R,3R)-adamantan-2-yl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 9);
[0126] 2,6-Diisopropylphenyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 10);
[0127] Among the above, compounds 1, 2, 5, 7, 8 and 10 are more preferred, compounds 1, 2, 5, 7 and 8 are further preferred, and compounds 1, 2, 7 and 8 are particularly preferred.
[0128] The compound represented by formula (1) can be synthesized by the methods described in Examples 1 to 10 described later, and specifically, can be synthesized by the following method.
[0129] [Chemical formula 8]
[0130]
[0131] Step A is a step of protecting the hydroxyl group and carboxyl group of (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoic acid as a starting compound with a protecting group A and a protecting group B, respectively. The protecting group A and the protecting group B are the same protecting groups.
[0132] As an example, when ethoxymethyl is used as the protecting group A and the protecting group B, a compound protected by the protecting group A and the protecting group B can be obtained by adding chloromethyl ethyl ether to a mixture of a starting compound and a solvent (e.g., N,N-diisopropylethylamine and dichloromethane) under ice cooling and stirring to react.
[0133] As another example, when 2-(trimethylsilyl)ethoxymethyl is used as the protecting group A and the protecting group B, 2-(trimethylsilyl)ethoxymethyl chloride is added to a mixture of a starting compound and a solvent (e.g., N,N-diisopropylethylamine and dichloromethane) under ice cooling and stirred to react, thereby obtaining a compound protected by the protecting group A and the protecting group B.
[0134] Step B is a step of removing the protecting group A which is the protecting group of the carboxyl group in the compound obtained in Step A.
[0135] The protecting group A can be removed by adding an aqueous solution of potassium hydroxide to a mixture of the compound obtained in step A and a solvent (eg, tetrahydrofuran, ethanol, etc.), followed by stirring while heating (eg, 30 to 50° C.).
[0136] Step C is to introduce R into the deprotected carboxyl group of the compound obtained in step B. 201 The process of the cyclic hydrocarbon group represented by R 201 The definition of is as described in this specification.
[0137] To the compound obtained in step B, R 201 The reaction of step C can be carried out by adding 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and N,N-dimethylaminopyridine to a mixture of an alcohol represented by -OH and a solvent (e.g., N,N-diisopropylethylamine and dichloromethane), and stirring the mixture while heating (e.g., 30 to 50° C.).
[0138] Step D is a step of removing the protecting group B which is the protecting group of the hydroxyl group in the compound obtained in step C.
[0139] For example, when the protecting group B is an ethoxymethyl group, the protecting group B can be removed by adding trifluoroacetic acid to a mixture of the compound obtained in step C, water and a solvent (eg, dichloromethane) under ice cooling and stirring at room temperature.
[0140] As another example, when the protecting group B is 2-(trimethylsilyl)ethoxymethyl, the protecting group B can be removed by adding a tetrabutylammonium fluoride-tetrahydrofuran solution to a solution of the compound obtained in step C and a solvent (e.g., N,N'-dimethylpropyleneurea), and stirring while heating (e.g., 70 to 90°C).
[0141] Step E is to introduce R into the hydroxyl group of the compound obtained in step D. 102 The step of removing the substituent represented by R 102 The definition of is as described in this specification.
[0142] The content of the compound represented by formula (1) is preferably 10 to 80 mol %, more preferably 10 to 60 mol %, and even more preferably 30 to 60 mol % based on the total lipids.
[0143] <Lipid composition>
[0144] The lipid composition of the present invention comprises a compound represented by the above formula (1) and at least one lipid. By adopting the above structure, the effect of nucleic acid cell introduction can be effectively exerted, that is, excellent nucleic acid delivery efficiency can be achieved, which is the knowledge first discovered in the present invention.
[0145] The at least one lipid is not particularly limited, but preferably at least one of ionizable lipids, neutral lipids, and lipids with nonionic hydrophilic polymers. In particular, it is preferred that the lipid composition of the present invention comprises all of ionizable lipids, neutral lipids, and lipids with nonionic hydrophilic polymers. As the ionizable lipid used in the lipid composition of the present invention, it is preferably a cationizable lipid, more preferably a cationizable amino lipid, and further preferably a lipid represented by formula (2) or a salt thereof.
[0146] <Lipid represented by formula (2) or a salt thereof>
[0147] The lipid composition of the present invention may contain a lipid represented by the following formula (2) or a salt thereof.
[0148] [Chemical formula 9]
[0149]
[0150] In the formula,
[0151] X stands for -NR 1 -or-O-,
[0152] R 1 represents a hydrogen atom, a hydrocarbon group having 6 to 24 carbon atoms, or R 21 -L 1 -R 22 - represented by the group, R 21 represents a hydrocarbon group having 1 to 24 carbon atoms, L 1 means -O(CO)O-, -O(CO)-, -(CO)O-, -O- or
[0153] [Chemical formula 10]
[0154]
[0155] R 22 represents a hydrocarbon linking group having 1 to 18 carbon atoms and being a divalent linking group,
[0156] R 2 and R 3 Each independently represents a hydrogen atom, a hydrocarbon group having 3 to 24 carbon atoms, or R 31 -L 2 -R 32 - represented by the group, R 31 represents a hydrocarbon group having 1 to 24 carbon atoms, L 2 means -O(CO)O-, -O(CO)-, -(CO)O-, -O- or
[0157] [Chemical formula 11]
[0158]
[0159] R 32 represents a hydrocarbon linking group having 1 to 18 carbon atoms and being a divalent linking group,
[0160] R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 each independently represents a hydrogen atom or an optionally substituted alkyl group having 1 to 18 carbon atoms,
[0161] R 4 With R 5 , R 10 With R 5 , R 5 With R 12 , R4 With R 6 , R 5 With R 6 , R 6 With R 7 , R 6 With R 10 , R 12 With R 7 , and R 7 With R 8 Any one or more of the groups may be linked to each other to form a 4- to 7-membered ring that may contain an O atom,
[0162] The substituent on the alkyl group having 1 to 18 carbon atoms which may be substituted is hydroxyl, carboxyl, -NR 45 R 46 The amino group, substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, -O(CO)OR 41 、-O(CO)-R 42 、-(CO)OR 43 OR 44 The group represented by R 41 , R 42 , R 43 , R 44 , R 45 and R 46 each independently represents a hydrocarbon group having 1 to 18 carbon atoms,
[0163] The substituents on the substituted or unsubstituted aryl group and the substituted or unsubstituted heteroaryl group are alkyl groups having 1 to 18 carbon atoms, hydroxyl groups, carboxyl groups, -NR 45 R 46 The amino group, -O(CO)OR 41 、-O(CO)-R 42 、-(CO)OR 43 OR 44 The group represented by R 41 , R 42 , R 43 , R 44 , R 45 and R 46 each independently represents a hydrocarbon group having 1 to 18 carbon atoms,
[0164] a, b, c and d each independently represent an integer of 0 to 3, wherein a+b is 1 or more, and c+d is 1 or more.
[0165] As R 1 The hydrocarbon group having 6 to 24 carbon atoms and R 2 and R 3The hydrocarbon group having 3 to 24 carbon atoms in is preferably an alkyl, alkenyl or alkynyl, and more preferably an alkyl or alkenyl. The alkyl group having 6 to 24 carbon atoms and the alkyl group having 3 to 24 carbon atoms may be straight chain or branched, and may be chain-like or cyclic. The alkyl group having 6 to 24 carbon atoms is preferably an alkyl group having 6 to 20 carbon atoms, and the alkyl group having 3 to 24 carbon atoms is more preferably an alkyl group having 6 to 20 carbon atoms. Specifically, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, trimethyldodecyl (preferably 3,7,11-trimethyldodecyl), tetradecyl, pentadecyl, hexadecyl, tetramethylhexadecyl (preferably 3,7,11,15-tetramethylhexadecyl), heptadecyl, octadecyl, nonadecyl, eicosyl and the like can be cited. The alkenyl group having 6 to 24 carbon atoms and the alkenyl group having 3 to 24 carbon atoms may be straight chain or branched, and may be chain-like or cyclic. The alkenyl group having 6 to 24 carbon atoms is preferably an alkenyl group having 6 to 20 carbon atoms, and the alkenyl group having 3 to 24 carbon atoms is more preferably an alkenyl group having 6 to 20 carbon atoms. Specific examples thereof include hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, dodecadienyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl (preferably (Z)-hexadec-9-enyl), hexadecadienyl, heptadecenyl (preferably (Z)-heptadec-8-enyl), heptadecadienyl (preferably (8Z,11Z)-heptadec-8,11-dienyl), octadecenyl (preferably (Z)-octadec-9-enyl), octadecadienyl (preferably (9Z,12Z)-octadecadienyl-9,12-dienyl), nonadecenyl, eicosenyl (preferably (Z)-eicos-11-enyl), and eicosadienyl (preferably (11,14)-eicos-11,14-dienyl). The alkynyl group having 6 to 24 carbon atoms is preferably an alkynyl group having 6 to 20 carbon atoms, and the alkynyl group having 3 to 24 carbon atoms is more preferably an alkynyl group having 6 to 20 carbon atoms. Specifically, hexynyl, heptynyl, octynyl, nonynyl, decynyl, undecynyl, dodecynyl, tetradecynyl, pentadecynyl, hexadecynyl, heptadecinyl, octadecynyl, etc. can be cited. The above alkenyl groups preferably have 1 or 2 double bonds, and the alkynyl groups preferably have 1 or 2 triple bonds.
[0166] As for R 21 and R 31The hydrocarbon group having 1 to 24 carbon atoms is preferably an alkyl group having 10 to 24 carbon atoms, an alkenyl group having 10 to 24 carbon atoms, or an alkynyl group having 10 to 24 carbon atoms. The alkyl group having 10 to 24 carbon atoms may be a straight chain or a branched chain, and may be a chain or a ring. The alkyl group having 10 to 24 carbon atoms is preferably an alkyl group having 12 to 24 carbon atoms. Specifically, there can be mentioned decyl, undecyl, dodecyl, tridecyl, trimethyldodecyl (preferably 3,7,11-trimethyldodecyl), tetradecyl, pentadecyl, hexadecyl, tetramethylhexadecyl (preferably 3,7,11,15-tetramethylhexadecyl), heptadecyl, octadecyl, 2-butylhexyl, 2-butyloctyl, 1-pentylhexyl, 2-pentylheptyl, 3-pentyloctyl, 1-hexylheptyl, 1-hexylnonyl, 2 -hexyloctyl, 2-hexyldecyl, 3-hexylnonyl, 1-heptyloctyl, 2-heptylnonyl, 2-heptylundecyl, 3-heptyldecyl, 1-octylnonyl, 2-octyldecyl, 2-octyldodecyl, 3-octylundecyl, 2-nonylundecyl, 3-nonyldodecyl, 2-decyldodecyl, 2-decyltetradecyl, 3-decyltridecyl, 2-(4,4-dimethylpentan-2-yl)-5,7,7-trimethyloctyl, etc. The alkenyl group having 10 to 24 carbon atoms may be straight chain or branched, and may be chain or cyclic. Specifically, there can be mentioned decenyl, undecenyl, dodecenyl, dodecadienyl, tridecenyl (preferably (Z)-tridec-8-enyl), tetradecenyl (preferably tetradec-9-enyl), pentadecenyl (preferably (Z)-pentadeca-8-enyl), hexadecenyl (preferably (Z)-hexadec-9-enyl), hexadecadienyl, heptadecaenyl (preferably (Z)-heptadec-8-enyl), heptadecadienyl (preferably (8Z,11Z)-heptadec-8,11-dienyl), octadecenyl (preferably (Z)-octadec-9-enyl), octadecadienyl (preferably (9Z,12Z)-octadecadienyl) etc. Alkynyl groups having 10 to 24 carbon atoms may be straight chain or branched chain, and may be chain or cyclic. Specific examples include decynyl, undecynyl, dodecynyl, tetradecynyl, pentadecynyl, hexadecynyl, heptadecinyl, octadecynyl, etc. The alkenyl groups preferably have one or two double bonds, and the alkynyl groups preferably have one or two triple bonds.
[0167] As for R 22 and R 32The divalent linking group and the hydrocarbon linking group having 1 to 18 carbon atoms are preferably an alkylene group having 1 to 18 carbon atoms or an alkenylene group having 2 to 18 carbon atoms. The alkylene group having 1 to 18 carbon atoms may be a straight chain or a branched chain, and may be a chain or a ring. The number of carbon atoms is preferably 1 to 12, more preferably 1 to 10 carbon atoms, and further preferably 2 to 10 carbon atoms. Specifically, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, decamethylene, undecamethylene, dodecamethylene, etc. may be cited. The alkenylene group having 2 to 18 carbon atoms may be a straight chain or a branched chain, and may be a chain or a ring. The number of carbon atoms is preferably 1 to 12, and more preferably 2 to 10 carbon atoms.
[0168] As L 1 The preferred range is preferably -O(CO)O-, -O(CO)- or -(CO)O-, and more preferably -O(CO)- or -(CO)O-.
[0169] As L 2 The preferred range is preferably -O(CO)O-, -O(CO)- or -(CO)O-, and more preferably -O(CO)- or -(CO)O-.
[0170] About R 4 , R 6 , R 9 , R 10 , R 11 and R 12 The alkyl group having 1 to 18 carbon atoms which may be substituted may be straight chain or branched chain, and may be chain or cyclic. The number of carbon atoms is preferably 1 to 12. Specifically, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, cyclohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, etc. may be mentioned. When the alkyl group has a substituent, the substituent is preferably hydroxyl, carboxyl, -O(CO)OR 41 、-O(CO)-R 42 、-(CO)OR 43 OR 44 The group represented by is more preferably -O(CO)-R 42 or-(CO)OR 43 The group represented.
[0171] About R 5 , R 7 and R 8The alkyl group having 1 to 18 carbon atoms which may be substituted may be straight chain or branched chain, and may be chain or cyclic. The number of carbon atoms is preferably 1 to 12, and more preferably 1 to 8. Specifically, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, cyclohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, etc. may be mentioned. When the alkyl group has a substituent, the substituent is preferably hydroxyl, carboxyl, -O(CO)OR 41 、-O(CO)-R 42 、-(CO)OR 43 OR 44 The group represented by -O(CO)-R 42 、-(CO)OR 43 The group represented.
[0172] Examples of the 4- to 7-membered ring which may contain an O atom include an azetidine ring, a pyrrolidine ring, a piperidine ring, a morpholine ring, and a cycloheximide ring. A 6-membered ring is preferred, and a piperidine ring and a morpholine ring are more preferred.
[0173] About R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 , when the substituent in the alkyl group having 1 to 18 carbon atoms which may be substituted is a substituted or unsubstituted aryl group, the aryl group preferably has 6 to 22 carbon atoms, more preferably 6 to 18 carbon atoms, and still more preferably 6 to 10 carbon atoms. Specifically, phenyl, naphthyl, anthracenyl, phenanthrenyl, etc. are mentioned. As the substituent on the aryl group, alkyl group having 1 to 18 carbon atoms, hydroxyl, carboxyl, -NR 45 R 46 The amino group, -O(CO)OR 41 、-O(CO)-R 42 、-(CO)OR 43 OR 44 The group represented by is more preferably a hydroxyl group or a carboxyl group. Specific examples of the substituted aryl group include hydroxyphenyl and carboxylphenyl.
[0174] About R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10, R 11 and R 12 When the substituent in the alkyl group having 1 to 18 carbon atoms which may be substituted is a substituted or unsubstituted heteroaryl group, the heteroaryl group preferably has 1 to 12 carbon atoms, and more preferably has 1 to 6 carbon atoms. Specifically, pyridyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, oxazolyl, etc. are mentioned. As the substituent on the heteroaryl group, alkyl group having 1 to 18 carbon atoms, hydroxyl, carboxyl, -NR 45 R 46 The amino group, -O(CO)OR 41 、-O(CO)-R 42 、-(CO)OR 43 OR 44 The group represented by is more preferably a hydroxyl group or a carboxyl group. Specific examples of the substituted or unsubstituted heteroaryl group include a hydroxypyridyl group, a carboxylpyridyl group, and a pyridonyl group.
[0175] As for R 41 , R 42 , R 43 , R 44 , R 45 and R 46The hydrocarbon group having 1 to 18 carbon atoms is preferably an alkyl group having 1 to 18 carbon atoms, an alkenyl group having 2 to 18 carbon atoms, or an alkynyl group having 2 to 18 carbon atoms, and more preferably an alkyl group having 1 to 18 carbon atoms or an alkenyl group having 2 to 18 carbon atoms. The alkyl group having 1 to 18 carbon atoms may be straight-chain or branched, and may be chain-shaped or cyclic. The number of carbon atoms is preferably 3 to 18, and more preferably 5 to 18 carbon atoms. Specifically, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, cyclohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, trimethyldodecyl (preferably 3,7,11-trimethyldodecyl), tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, and the like. The alkenyl group having 2 to 18 carbon atoms may be straight-chain or branched, and may be chain-shaped or cyclic. The number of carbon atoms is preferably 3-18, more preferably 5-18. Specific examples thereof include allyl, isoprenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl (preferably (Z)-2-nonenyl or (E)-2-nonenyl), decenyl, undecenyl, dodecenyl, dodecadienyl, tridecenyl (preferably (Z)-trideca-8-enyl), tetradecenyl (preferably tetradec-9-enyl), pentadecenyl (preferably (Z)-pentadeca-8-enyl), hexadecenyl (preferably (Z)-hexadec-9-enyl), hexadecadienyl, heptadecaenyl (preferably (Z)-heptadeca-8-enyl), heptadecaadienyl (preferably (8Z,11Z)-heptadeca-8,11-dienyl), octadecenyl (preferably (Z)-octadec-9-enyl), octadecadienyl (preferably (9Z,12Z)-octadecadienyl) and the like. The alkynyl group having 2 to 18 carbon atoms may be straight chain or branched chain, and may be chain or cyclic. The number of carbon atoms is preferably 3 to 18, and more preferably 5 to 18. Specifically, there may be mentioned propargyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, undecynyl, dodecynyl, tetradecynyl, pentadecynyl, hexadecynyl, heptadecenyl, octadecynyl, and the like.
[0176] When X represents -NR 1 -, R 1 Preferably, it is a hydrocarbon group having 6 to 24 carbon atoms or R 21 -L 1 -R 22 - represented by a group. In this case, preferably R 2 and R 3 One of them is a hydrogen atom, R 2 and R 3 The other one is a hydrocarbon group having 6 to 24 carbon atoms or R 31 -L 2 -R32 - represents a group.
[0177] When X represents -O-, R 2 and R 3 Each of the above is preferably independently a hydrocarbon group having 6 to 24 carbon atoms or R 31 -L 2 -R 32 - represents a group.
[0178] R 4 , R 6 , R 9 , R 10 , R 11 and R 12 Preferred is a hydrogen atom.
[0179] R 5 Preferably, a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, or a -O(CO)-R 42 or-(CO)OR 43 An alkyl group having 1 to 18 carbon atoms which may be substituted by an aryl group, an alkyl group having 1 to 18 carbon atoms which may be substituted by a hydroxyl group, and when it is an alkyl group, it may be combined with R 4 , R 6 , R 10 and R 12 are connected to each other to form a ring which may contain an O atom. Among them, an alkyl group having 1 to 18 carbon atoms, which may be -O(CO)-R 42 or-(CO)OR 43 An alkyl group having 1 to 18 carbon atoms which may be substituted by an alkyl group, an alkyl group having 1 to 12 carbon atoms which may be substituted by an aryl group, or an alkyl group having 1 to 8 carbon atoms which may be substituted by a hydroxyl group, more preferably an alkyl group having 1 to 18 carbon atoms, or an alkyl group having -O(CO)-R 42 or-(CO)OR 43 A substituted alkyl group having 1 to 18 carbon atoms.
[0180] Preferred R 7 and R 8 are each independently a hydrogen atom, a hydrocarbon group having 1 to 18 carbon atoms, or -O(CO)-R 42 or-(CO)OR 43 an alkyl group having 1 to 18 carbon atoms which may be substituted with an aryl group, an alkyl group having 1 to 8 carbon atoms which may be substituted with a hydroxyl group, or an alkyl group having 1 to 8 carbon atoms which may be substituted with a hydroxyl group, or R 7 With R 8 They are linked to each other to form a 4- to 7-membered ring which may contain an O atom.
[0181] R 5 With R 7or R 8 They are not connected to each other and do not form a ring.
[0182] a+b is preferably 1 or 2, more preferably 1. c+d is preferably 1 or 2, more preferably 1.
[0183] In a preferred embodiment, the lipid represented by formula (2) is a lipid represented by the following formula (3).
[0184] [Chemical formula 12]
[0185]
[0186] In the formula,
[0187] R 2 and R 3 are each independently a hydrocarbon group having 3 to 24 carbon atoms and containing one or more unsaturated bonds, or
[0188] R 2 and R 3 R 31 -L 2 -R 32 - a group represented by, or
[0189] R 2 and R 3 One of them is R 31 -L 2 -R 32 -, the other is a hydrocarbon group having 3 to 24 carbon atoms,
[0190] R 31 represents a hydrocarbon group having 1 to 24 carbon atoms,
[0191] L 2 means -O(CO)O-, -O(CO)-, -(CO)O-, -O- or
[0192] [Chemical formula 13]
[0193]
[0194] R 32 is a divalent linking group, representing a hydrocarbon linking group having 1 to 18 carbon atoms,
[0195] R 5 Represents -O(CO)-R 42 or can be -(CO)OR 43 Substituted alkyl having 1 to 18 carbon atoms, R 42 and R 43 each independently represents a hydrocarbon group having 1 to 18 carbon atoms,
[0196] R 7 and R 8 each independently represents an alkyl group having 1 to 4 carbon atoms,
[0197] e means 2 or 3.
[0198] In formula (3), preferably R 2 and R 3 One of them is R 31 -L 2 -R 32 -, and the other is a hydrocarbon group having 3 to 24 carbon atoms. In formula (3), preferably L 2 It represents -O(CO)- or -(CO)O-.
[0199] The lipid represented by formula (2) can form a salt.
[0200] Examples of the salt in the basic group include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid and sulfuric acid; salts with organic carboxylic acids such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid.
[0201] Examples of the salt of the acidic group include salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and salts with nitrogen-containing organic bases such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-diphenylhydroxymethylamine, and N,N'-dibenzylethylenediamine.
[0202] Among the above-mentioned salts, pharmaceutically acceptable salts are preferred.
[0203] Preferred specific examples of the lipid represented by formula (2) include 2-pentylheptyl 6-(2-(decanoyloxy)ethyl)-3-ethyl-12-hexyl-10-oxo-9,11-dioxa-3,6-diazahexadecane-16-oate (see WO2021 / 095876).
[0204] The lipid represented by formula (2) and a method for producing the same are described in WO2019 / 235635 and WO2021 / 095876.
[0205] In the lipid composition of the present invention, the content of the lipid represented by formula (2) or a salt thereof is preferably 20 mol% to 80 mol%, more preferably 30 mol% to 70 mol%, and further preferably 40 mol% to 60 mol%, relative to the mass of the whole fat.
[0206] <Neutral lipids>
[0207] The lipid composition of the present invention may comprise neutral lipids.
[0208] As the neutral lipid, a diionic lipid is preferred.
[0209] As the zwitterionic lipid, preferably a phospholipid, specifically, phosphatidylcholine, phosphatidylethanolamine or sphingomyelin etc. can be mentioned. As the phospholipid, preferably a phospholipid having a choline group such as phosphatidylcholine etc. As the zwitterionic lipid, it can be used alone or in combination with a variety of different neutral lipids.
[0210] The phosphatidylcholine is not particularly limited, and examples thereof include soybean lecithin (SPC), hydrogenated soybean lecithin (HSPC), egg yolk lecithin (EPC), hydrogenated egg yolk lecithin (HEPC), dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dilauroylphosphatidylcholine (DLPC), 1-palmitoyl-2-oleoylphosphatidylcholine (POPC), etc. Among them, dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC) and dilauroylphosphatidylcholine (DLPC) are preferred, and distearoylphosphatidylcholine (DSPC) is particularly preferred.
[0211] The phosphatidylethanolamine is not particularly limited, but examples thereof include dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylethanolamine (DOPE), dilinoleoylphosphatidylethanolamine (DL oPE), diphytanoylphosphatidylethanolamine (D(Phy)PE), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), ditetradecylphosphatidylethanolamine, dihexadecylphosphatidylethanolamine, dioctadecylphosphatidylethanolamine, and diphytylphosphatidylethanolamine.
[0212] The sphingomyelin (SM) is not particularly limited, and examples thereof include sphingomyelin derived from egg yolk and sphingomyelin derived from milk.
[0213] In the lipid composition of the present invention, the content of the neutral lipid is preferably 1 to 30 mol %, more preferably 5 to 25 mol %, and even more preferably 7 to 23 mol % based on the total lipids.
[0214] <Lipids with nonionic hydrophilic polymers>
[0215] The lipid composition of the present invention may contain lipids having nonionic hydrophilic macromolecules.
[0216] The lipid having a nonionic hydrophilic macromolecular weight preferably contains an acyl group, and the carbon chain length of the acyl group is preferably 8 to 26.
[0217] Examples of nonionic hydrophilic polymers are not particularly limited and include nonionic vinyl polymers, nonionic polyamino acids, nonionic polyesters, nonionic polyethers, nonionic natural polymers, nonionic modified natural polymers, and block polymers or graft copolymers having two or more of these polymers as structural units.
[0218] Among these nonionic hydrophilic polymers, preferred are nonionic polyethers, nonionic polyesters, nonionic polyamino acids or nonionic synthetic polypeptides, more preferred are nonionic polyethers or nonionic polyesters, still more preferred are nonionic polyethers or nonionic monoalkoxy polyethers, and particularly preferred are polyethylene glycol (hereinafter, polyethylene glycol is also referred to as PEG).
[0219] The lipid having a nonionic hydrophilic polymer is not particularly limited, and examples thereof include PEG-modified phosphoethanolamine, diacylglycerol PEG derivatives, monoacylglycerol PEG derivatives, dialkylglycerol PEG derivatives, cholesterol PEG derivatives, ceramide PEG derivatives, etc. Among these, monoacylglycerol PEG or diacylglycerol PEG is preferred.
[0220] The number of carbon atoms in the alkyl chain of the lipid having a nonionic hydrophilic polymer is preferably 8 to 26, more preferably 10 to 22.
[0221] The weight average molecular weight of the nonionic hydrophilic polymer is preferably 100 to 10,000, more preferably 500 to 5,000, and even more preferably 750 to 3,000.
[0222] The nonionic hydrophilic polymer may be branched or may have a substituent such as a hydroxymethyl group.
[0223] Preferred examples of lipids having a nonionic hydrophilic polymer include DMG-PEG2000 (also referred to as DMG-PEG), stearic acid PEG, and stearyl ether PEG having the following structure.
[0224] Particularly preferred specific examples of lipids having a nonionic hydrophilic polymer are shown below.
[0225] [Chemical formula 14]
[0226]
[0227] In the lipid composition of the present invention, the blending amount of lipids having nonionic hydrophilic polymers is preferably 0.1 to 10 mol %, more preferably 0.3 to 8 mol %, further preferably 0.5 to 5 mol %, and particularly preferably 1 to 3 mol % relative to the total lipids.
[0228] <Nucleic Acid>
[0229] The lipid composition of the present invention may include nucleic acids. As nucleic acids, plasmids, single-stranded DNA, double-stranded DNA, siRNA (small interfering RNA), miRNA (micro RNA), mRNA, antisense oligonucleotides, ribozymes (also known as ASOs), ribozymes, aptamers, decoy nucleic acids, gRNA used in genome editing, etc., may include any of them. In addition, modified nucleic acids may also be included.
[0230] In the lipid composition of the present invention, the weight ratio of lipid to nucleic acid is preferably 5-100, more preferably 5-70, further preferably 5-40, and particularly preferably 5-35.
[0231] <Method for producing lipid composition>
[0232] The method for producing the lipid composition of the present invention is described.
[0233] The method for producing the lipid composition is not particularly limited, and can be produced by dissolving all or part of the oil-soluble components of the constituent components of the lipid composition in an organic solvent, etc. to form an oil phase, dissolving the water-soluble components in water to form an aqueous phase, and mixing the oil phase and the aqueous phase. A micro mixer can be used for mixing, and emulsification can also be performed using an emulsifier such as a homogenizer, an ultrasonic emulsifier, a high-pressure jet emulsifier, etc.
[0234] Alternatively, the preparation can also be carried out by supplying a solution containing lipids to an evaporator or the like for vacuum drying or to a spray dryer or the like for spray drying to prepare a dry mixture containing lipids, adding the mixture to an aqueous solvent, and further emulsifying it using the above-mentioned emulsifier or the like.
[0235] As an example of a method for producing a lipid composition, there can be mentioned a method comprising the following steps:
[0236] A step (a) of dissolving a lipid component in an organic solvent to obtain an oil phase;
[0237] A step (b) of mixing the oil phase obtained in the step (a) and the aqueous phase containing nucleic acid;
[0238] A step (c) of diluting the mixed solution containing the oil phase and the aqueous phase obtained in step (b) to obtain a dispersion solution of the lipid composition containing nucleic acid; and
[0239] A step (d) of removing the organic solvent from the dispersion of the lipid composition obtained in the step (c).
[0240] In step (a), the lipid component is dissolved in an organic solvent (alcohol such as ethanol or ester, etc.). The total lipid concentration is not particularly limited, but is usually 1 mmol / L to 100 mmol / L, preferably 5 mmol / L to 50 mmol / L, and more preferably 10 mmol / L to 30 mmol / L.
[0241] In step (b), the aqueous phase can be obtained by dissolving a nucleic acid (e.g., siRNA, antisense oligonucleotide, mRNA, etc.) in water or a buffer. As required, components such as an antioxidant can be added. The ratio (volume ratio) of mixing the aqueous phase and the oil phase is preferably 5:1 to 1:1, more preferably 4:1 to 2:1.
[0242] In step (b), the mixed solution can be diluted with water or a buffer solution (eg, phosphate buffered saline (PBS) or the like).
[0243] In step (c), the method for removing the organic solvent from the dispersion of the lipid composition is not particularly limited, and a common method can be used. For example, the organic solvent can be removed by dialysis using phosphate-buffered saline.
[0244] The size of the lipid composition can be adjusted as needed. The method for adjusting the size is not particularly limited, but the particle size can be reduced using an extruder or the like.
[0245] <About lipid composition>
[0246] The lipid composition of the present invention can be a lipid particle. Lipid particles refer to particles composed of lipids, including lipid aggregates (e.g., lipid nanoparticles, etc.) formed by lipid aggregation, micelles, and compositions having any structure selected from liposomes, but as long as it is a composition comprising lipids, the structure of the lipid particles is not limited to these.
[0247] The morphology of the lipid composition can be confirmed by electron microscopic observation or structural analysis using X-rays. For example, by using the method of Cryo transmission electron microscopy (CryoTEM method), it can be confirmed whether the lipid particles have a lipid bimolecular membrane structure (lamellar structure) and an inner water layer, such as liposomes, or whether there is a core with high electron density inside the particle and filled with a structure of constituents headed by lipids. By measuring with small angle X-ray scattering (SAXS), it is also possible to confirm the presence or absence of a lipid bimolecular membrane structure (lamellar structure) for lipid particles.
[0248] When the lipid composition of the present invention is a particle, the particle size is not particularly limited, but is preferably 10 to 1000 nm, more preferably 30 to 500 nm, and further preferably 50 to 250 nm. The particle size of lipid particles can be measured by a common method (e.g., dynamic light scattering, laser diffraction, etc.).
[0249] <Utilization of lipid composition>
[0250] As an example of utilizing the lipid composition in the present invention, nucleic acid (eg, gene, etc.) can be introduced into cells by introducing the lipid composition containing nucleic acid into cells. That is, the lipid composition of the present invention can be used as a composition for introducing nucleic acid into cells.
[0251] Furthermore, the lipid composition of the present invention can be used as a pharmaceutical composition for nucleic acid delivery in vivo.
[0252] And, when the lipid composition in the present invention includes a nucleic acid with pharmaceutical use, the lipid composition can be administered to a living body as a nucleic acid drug. When the lipid composition in the present invention is used as a nucleic acid drug, the lipid composition of the present invention can be administered to a living body alone or mixed with a pharmaceutically acceptable carrier (e.g., a dosing medium such as a physiological saline or a phosphate buffer). That is, the lipid composition of the present invention can further include a pharmaceutically acceptable carrier.
[0253] The concentration of the lipid composition in the mixture with the pharmacologically acceptable carrier is not particularly limited, and can generally be set to 0.05% to 90% by mass. In addition, other pharmaceutically acceptable additives such as pH adjusting buffers, osmotic pressure regulators, etc. may also be added to the nucleic acid drug comprising the lipid composition of the present invention.
[0254] The route of administration during the administration of the lipid composition of the present invention is not particularly limited, and any method can be used for administration. As the method of administration, oral administration, parenteral administration (intraarticular administration, intravenous administration, intraarterial administration, subcutaneous administration, intradermal administration, intravitreal administration, intraperitoneal administration, intramuscular administration, intravaginal administration, intravesical administration, intrathecal administration, pulmonary administration, rectal administration, colon administration, buccal administration, nasal administration, intracisternal administration, suction, etc.) can be enumerated. Parenteral administration is preferably used, and as the method of administration, it is preferably intravenous injection, subcutaneous injection, intradermal injection or intramuscular injection. As administration, nucleic acid delivery is preferably carried out by topical administration in vivo. About the lipid composition of the present invention, it is also possible to administer by being directly injected into the disease site.
[0255] The dosage form of the lipid composition of the present invention is not particularly limited. When oral administration is performed, the lipid composition of the present invention can be combined with appropriate excipients and used in the form of tablets, buccal tablets, capsules, pills, suspensions, syrups, etc. In addition, in preparations suitable for parenteral administration, additives such as antioxidants, buffers, antibacterial agents, isotonic sterile injections, suspending agents, solubilizers, thickeners, stabilizers or preservatives can be appropriately included.
[0256] <Nucleic acid delivery carrier>
[0257] The lipid composition of the present invention can keep nucleic acid with high inclusion rate, so it is very useful as nucleic acid delivery carrier. According to utilizing nucleic acid delivery carrier of the present invention, for example, nucleic acid etc. can be introduced into cells by mixing the obtained lipid composition with nucleic acid in vitro (in vitro) or in vivo (in vivo) for transfection. And, utilizing nucleic acid delivery carrier of the present invention is also useful as nucleic acid delivery carrier in nucleic acid drug. That is, lipid composition of the present invention is useful as a composition for external or in vivo (preferably in vivo) nucleic acid delivery.
[0258] Next, the present invention will be described with reference to Examples, but the present invention is not limited to these.
[0259] Example
[0260] Unless otherwise specified, purification by column chromatography was performed using an automatic purification apparatus ISOLERA (Bio otage), a medium-pressure fractionation purification apparatus Purif-espoir-2 (Shoko Science Co., Ltd.), or a medium-pressure liquid chromatography YFLCW-prep 2XY (YAMAZEN CORPORATION).
[0261] Unless otherwise specified, the carrier used in the silica gel column chromatography was Chromatorex Q-Pack SI 50 (FUJI SILYSIA CHEMICAL LTD.), High-Flash Column W001, W002, W003, W004 or W005 (YAMAZEN CORPORATION).
[0262] As the NH silica gel, Chromatorex Q-Pack NH 60 (FUJI SILYSIA CHEMICAL LTD.) was used.
[0263] The NMR spectrum was measured using Bruker AVNEO400 (manufactured by Bruker Corporation) using tetramethylsilane as an internal standard, and the total δ value was expressed in ppm.
[0264] clogP was calculated using ChemDraw Professional Version: 19.1.0.8 (manufactured by Perkin Elmer Co., Ltd.).
[0265] [Example 1] (1)
[0267] [Chemical formula 15]
[0268]
[0269] Chloromethyl ethyl ether (4.5 mL) was added dropwise to a mixture of (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoic acid (6.00 g), N,N-diisopropylethylamine (13.5 mL) and dichloromethane (60 mL) under ice-cooling, and the mixture was stirred at the same temperature for 1 hour. Water (60 mL) was added dropwise to the reaction mixture under ice-cooling, the organic layer was separated, and the aqueous layer was extracted with a mixed solution of hexane (15 mL) and ethyl acetate (15 mL). The organic layer and the extract were combined, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel chromatography (ethyl acetate-hexane) to obtain ethoxymethyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (6.74 g) as a colorless oil.
[0270] 1 H-NMR (CDCl 3 )δ:5.37-5.32(1H,m),5.28(2H,s),4.74(2H,s),3.68(2H,q,J=7.08Hz),3.61(2H,q ,J=7.08Hz),3.49-3.39(1H,m),2.44-2.20(4H,m),2.04-0.82(33H,m),0.68(3H,s).
[0271] To a mixture of ethoxymethyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (6.74 g), tetrahydrofuran (20 mL) and ethanol (20 mL) was added a solution of potassium hydroxide (2.72 g) in water (10 mL), followed by stirring at 40° C. for 2 hours. A 5 mol / L aqueous hydrochloric acid solution (6 mL) was added dropwise to the reaction mixture under ice cooling, and ethyl acetate (40 mL) was added, and the organic layer was separated and then washed with water and a saturated aqueous sodium chloride solution. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoic acid (5.29 g) as a white solid.
[0272] 1H-NMR (CDCl 3 )δ:5.37-5.32(1H,m),4.74(2H,s),3.61(2H,q,J=7.08Hz),3.49-3.39(1H,m),2.44-2.20(4H,m),2.04-0.82(30H,m),0.68(3H,s).
[0273] To a mixture of (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoic acid (0.50 g), cis-4-tert-butylcyclohexanol (0.20 g), N,N-diisopropylethylamine (1.0 mL) and dichloromethane (5.0 mL) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.33 g) and N,N-dimethylaminopyridine (0.14 g), followed by stirring at 40° C. for 1 hour. Water (5 mL) was added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel chromatography (ethyl acetate-hexane) to obtain (1s,4S)-4-(tert-butyl)cyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (0.57 g) as a colorless oil. (2)
[0275] [Chemical formula 16]
[0276]
[0277] Trifluoroacetic acid (1.0 mL) was added to a mixture of (1s,4S)-4-(tert-butyl)cyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (0.57 g), water (0.1 mL) and dichloromethane (4.0 mL) under ice cooling, and the mixture was stirred at room temperature for 30 minutes. A 10% aqueous potassium carbonate solution (20 mL) was added to the reaction mixture under ice cooling, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate-hexane), and then ethanol (10 mL) and water (1 mL) were added to the obtained solid, followed by stirring at 60° C. The mixture was cooled to room temperature, and the solid was filtered out, washed with a mixed solution of ethanol and water, and then dried under reduced pressure to obtain (1s, 4S)-4-(tert-butyl)cyclohexyl (R)-4-((3S, 8S, 9S, 10R, 13R, 14S, 17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 1) (0.25 g) as a white solid.
[0278] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),5.02-4.98(1H,m),3.57-3.47(1H,m),2.40-2.16(4H,m),2.04-1.76(8H,m),1.65-0.81(37H,m),0.68(3H,s).
[0279] clogP: 10.37
[0280] [Example 2]
[0281] [Chemical formula 17]
[0282]
[0283] Trimethylsilyl chloride (1.3 mL) was added to a mixture of (1r,4r)-4-(tert-butyl)cyclohexyl (R)-4-((3s,8s,9s,10r,13r,14s,17r)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (0.49 g), tetrabutylammonium bromide (3.4 g) and dichloromethane (10 mL) under ice cooling, and the mixture was stirred at the same temperature for 30 minutes. A 10% aqueous potassium carbonate solution (10 mL) was added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate-hexane), and ethanol (10 mL) and water (1 mL) were added to the obtained solid, and stirred at 60 ° C. After the obtained mixture was cooled to room temperature, the solid was filtered out, washed with a mixed solution of ethanol and water, and dried under reduced pressure to obtain a white solid (1r, 4R)-4-(tert-butyl)cyclohexyl (R)-4-((3S, 8S, 9S, 10R, 13R, 14S, 17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl) valerate (compound 2) (0.27 g).
[0284] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),4.67-4.57(1H,m),3.57-3.47(1H,m),2.36-2.13(4H,m),2.05-1.73(10H,m),1.65-0.78(35H,m),0.68(3H,s).
[0285] clogP: 10.37
[0286] [Example 3] (1)
[0288] [Chemical formula 18]
[0289]
[0290] To a mixture of (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoic acid (3.00 g), N,N-diisopropylethylamine (11.0 mL) and dichloromethane (30.0 mL) was added dropwise a mixture of 2-(trimethylsilyl)ethoxymethyl chloride (6.0 mL) and dichloromethane (6.0 mL) under ice-cooling, and the mixture was stirred at room temperature for 2 hours. After water (30 mL) was added dropwise to the reaction mixture under ice-cooling, the organic layer was separated, and the aqueous layer was extracted with a mixed solution of hexane and ethyl acetate. The organic layer and the extract were combined, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel chromatography (ethyl acetate-hexane) to obtain (2-(trimethylsilyl)ethoxy)methyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (5.53 g) as a colorless oil.
[0291] 1H-NMR (CDCl 3 )δ:5.37-5.32(1H,m),5.27(2H,s),4.71(2H,s),3.73-3.59(4H,m),3.50-3.39(1H, m),2.44-2.20(4H,m),2.02-0.82(31H,m),0.68(3H,s),0.023(9H,s),0.020(9H,s).
[0292] To a mixture of (2-(trimethylsilyl)ethoxy)methyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (5.53 g), tetrahydrofuran (16 mL) and ethanol (16 mL) was added a mixture of potassium hydroxide (0.89 g) and water (8 mL), followed by stirring at 40° C. for 2 hours. To the reaction mixture was added a mixture of 30% hydrochloric acid water (1.59 g) and water (8 mL) dropwise under ice cooling, followed by addition of ethyl acetate (16 mL), and the organic layer was separated and washed with water and a saturated sodium chloride aqueous solution. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and hexane was added to the obtained solid. After stirring under ice cooling, the solid was filtered out, washed with hexane, and dried under reduced pressure to obtain (R)-4-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoic acid (3.24 g) as a white solid.
[0293] 1H-NMR (CDCl 3 )δ:5.37-5.32(1H,m),4.71(2H,s),3.66-3.59(2H,m),3.50-3.39(1H,m),2.45-2.20(4H,m),2.03-0.82(29H,m),0.68(3H,s),0.02(9H,s).
[0294] To a mixture of (R)-4-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid (0.500 g), (-)-menthol (0.170 g), N,N-diisopropylethylamine (0.86 mL) and dichloromethane (5.00 mL) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.285 g) and N,N-dimethylaminopyridine (0.121 g), followed by stirring at 40° C. for 1 hour. Water (5 mL) was added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate-hexane) to obtain (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (0.571 g) as a colorless oil.
[0295] 1H-NMR (CDCl 3 )δ:5.37-5.32(1H,m),4.73(2H,s),4.67(1H,td,J=10.84Hz,4.36Hz),3.66-3.59(2H,m),3.50-3.3 9(1H,m),2.38-2.14(4H,m),2.05-0.80(44H,m),0.75(3H,d,J=6.92Hz),0.68(3H,s),0.02(9H,s). (2)
[0297] [Chemical formula 19]
[0298]
[0299] To a solution of (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (0.571 g) in N,N'-dimethylpropyleneurea (3 mL) was added 1 mol / L tetrabutylammonium fluoride-tetrahydrofuran solution (2.7 mL), and the mixture was stirred at 80°C for 9 hours. After the reaction mixture was cooled to room temperature, a 20% aqueous ammonium chloride solution (12 mL) and ethyl acetate (5 mL) were added, and the organic layer was separated. After washing with 20% aqueous ammonium chloride solution and saturated aqueous sodium chloride solution, the mixture was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel chromatography (ethyl acetate-hexane) to obtain (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 3) (0.123 g) as a white solid.
[0300] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),4.71-4.63(1H,m),3.57-3.47(1H,m),2.37-2.15(4H,m ),2.05-1.73(8H,m),1.72-0.80(34H,m),0.75(3H,d,J=6.96Hz),0.68(3H,s).
[0301] clogP: 10.49
[0302] [Example 4]
[0303] [Chemical formula 20]
[0304]
[0305] Zinc (II) bromide (0.9 g) was added to a dichloromethane (6 mL) solution of (1S,2S,5R)-2-isopropyl-5-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (0.637 g) synthesized by the same method as described in Example 3(1) under ice cooling, and the mixture was stirred at room temperature for 2 hours. A 20% aqueous ammonium chloride solution (12 mL) was added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate-hexane) to obtain colorless amorphous (1S,2S,5R)-2-isopropyl-5-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 4) (0.269 g).
[0306] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),5.20-5.16(1H,m),3.57-3.47(1H,m),2.38-2.17(4H,m),2.04-1.68(8H,m),1.65-0.80(37H,m),0.68(3H,s).
[0307] clogP: 10.49
[0308] [Example 5]
[0309] [Chemical formula 21]
[0310]
[0311] In Example 1(2), cyclooctyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate synthesized by the same method as described in Example 1(1) was used instead of (1s,4S)-4-(tert-butyl)cyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate. The same method as in Example 1 (2) was used to obtain cyclooctyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate as a white solid.
[0312] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),4.97-4.89(1H,m),3.57-3.47(1H,m),2.35-2.13(4H,m),2.04-1.93(2H,m),1.92-0.80(39H,m),0.68(3H,s).
[0313] clogP: 9.642
[0314] [Example 6]
[0315] [Chemical formula 22]
[0316]
[0317] In Example 4, cyclododecyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate synthesized by the same method as described in Example 1(1) was used instead of (1S,2S,4S)-2-isopropyl-4-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate. -((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate, except that a white solid cyclododecyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 6) was obtained in the same manner as in Example 4.
[0318] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),5.05-4.97(1H,m),3.57-3.47(1H,m),2.36-2.14(4H,m),2.04-1.93(2H,m),1.92-0.80(47H,m),0.68(3H,s).
[0319] clogP: 11.878
[0320] [Example 7]
[0321] [Chemical formula 23]
[0322]
[0323] In Example 4, (2R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl (4R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate synthesized by the same method as described in Example 1(1) was used instead of (1S,2S,4S)-2-isopropyl-4-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3 -((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate, except that the same method as in Example 4 was used to obtain (2R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl (4R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 7) as a white solid.
[0324] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),4.90-4.85(1H,m),3.57-3.47(1H,m),2.40-2.18(5H,m),2.05-0.80(42H,m),0.68(3H,s).
[0325] clogP: 10.356
[0326] [Example 8]
[0327] [Chemical formula 24]
[0328]
[0329] In Example 1(2), 1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl (4R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate synthesized by the same method as described in Example 1(1) was used instead of (1s,4S)-4-(tert-butyl)cyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate. The same method as in Example 1 (2) was used to obtain 1,3,3-trimethylbicyclo[2.2.1]heptane-2-yl (4R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate as a white solid.
[0330] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),4.35(1H,brs),3.57-3.47(1H,m),2.43-2.18(4H,m),2.05-0.83(40H,m),0.77(3H,s),0.68(3H,s).
[0331] clogP: 10.356
[0332] [Example 9]
[0333] [Chemical formula 25]
[0334]
[0335] In Example 2, (1R,3R)-adamantan-2-yl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate synthesized by the same method as described in Example 1(1) was used instead of (1R,4R)-4-(tert-butyl)cyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate. The same method as in Example 2 was used to obtain (1R,3R)-adamantan-2-yl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate as a white solid.
[0336] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),5.02-4.98(1H,m),3.57-3.47(1H,m),2.39-2.18(4H,m),2.04-1.76(8H,m),1.65-0.80(33H,m),0.68(3H,s).
[0337] clogP: 10.192
[0338] [Example 10]
[0339] [Chemical formula 26]
[0340]
[0341] In Example 4, 2,6-diisopropylphenyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate synthesized by the same method as described in Example 1(1) was used instead of (1S,2S,4S)-2-isopropyl-4-methylcyclohexyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-(ethoxymethoxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate. ((2-(Trimethylsilyl)ethoxy)methoxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate, except that 2,6-diisopropylphenyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoate (Compound 10) was obtained as a white solid in the same manner as in Example 4.
[0342] 1 H-NMR (CDCl 3 )δ:7.23-7.13(3H,m),5.37-5.33(1H,m),3.57-3.47(1H,m),2.96-2.84(2H,m),2.71-2.62(1H ,m),2.59-2.50(1H,m),2.36-2.19(2H,m),2.07-1.80(6H,m),1.65-0.80(33H,m),0.71(3H,s).
[0343] clogP: 9.856
[0344] [Comparative Example 1]
[0345] [Chemical formula 27]
[0346]
[0347] Potassium carbonate (0.277 g) was added to a mixture of (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl)pentanoic acid (0.500 g), 1-bromopentane (0.534 g) and N,N-dimethylformamide (2.5 mL), followed by stirring at 60° C. for 4 hours. Ethyl acetate (2.5 mL), hexane (2.5 mL) and water (2.5 mL) were added to the reaction mixture, and the organic layer was separated, washed twice with water (2.5 mL), dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. To the obtained residue was added ethanol (10 mL), and the mixture was stirred at 60° C., then cooled to room temperature, and water (5 mL) was added and stirred. The solid was filtered out, washed with a mixed solution of ethanol and water, and dried under reduced pressure to obtain pentyl (R)-4-((3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17 as a white solid.
[0348] -yl)pentanoate (Comparative Compound 1) (0.539 g).
[0349] 1 H-NMR (CDCl 3 )δ:5.37-5.33(1H,m),4.05(2H,t,J=6.8Hz),3.58-3.46(1H,m),2.40-2.15( 4H,m),2.05-1.92(2H,m),1.92-1.73(4H,m),1.66-0.82(30H),0.68(3H,s).
[0350] clogP: 8.609
[0351] <PTEN antisense oligonucleotide information>
[0352] PTEN (Phosphatase and Tensin Homolog Deleted from Chromosome 10) is an enzyme that catalyzes the dephosphorylation reaction of phosphatidylinositol-3,4,5-triphosphate, which is an inositol phospholipid.
[0353] Antisense oligonucleotide nucleic acid (PTEN aSO) against PTEN protein was purchased from Gene Design Co., Ltd. and Hokkaido System Science CO, Ltd. It is an oligonucleotide comprising 20 bases of phosphodiester bonds and is arranged as follows.
[0354] 5'-C(m)^T(m)^G(m)^C(m)^T(m)^a^g^c^c^t^c^t^g^g^a^T(m)^T(m)^T(m)^G(m)^A(m)-3'
[0355] Wherein, a represents 2'-deoxyadenosine, g represents 2'-deoxyguanosine, t represents thymine, and c represents 2'-deoxy-5-methylcytidine. (m) represents 2'-O-methoxyethyl (2'-MOE) modification, A(m) represents 2'-MOE-adenosine, G(m) represents 2'-MOE-guanosine, T(m) represents 2'-MOE-thymine, and C(m) represents 2'-MOE-5-methylcytidine. ^ represents phosphorothioate.
[0356] (Preparation of PTEN aSO-LNP)
[0357] The ionized lipids, phospholipids, sterols, and polyethylene glycol lipids (PEG lipids) shown in Table 1 were dissolved in ethanol at the molar ratios described in Table 1 so that the total lipid concentration became 20 mmol / L, thereby obtaining an oil phase.
[0358] The components used are shown below.
[0359] Ionized lipid: 2-pentylheptyl 6-(2-(decanoyloxy)ethyl)-3-ethyl-12-hexyl-10-oxo-9,11-dioxa-3,6-diazahexadecane-16-oate (refer to Example 135 of WO2021 / 095876) (labeled as Compound A in this application);
[0360] [Chemical formula 28]
[0361]
[0362] Phospholipids: DSPC (1,2-Distearoyl-sn-glycero-3-phosphocholine, product name: COaTSOME MC-8080; NOF corporation);
[0363] PEG lipid: DMG-PEG2000 (1,2-dimyristoyl-rac-glycero-3-methoxypolyethyleneglycol) (Product name: SUNB RIGHT (registered trademark) GM-020; NOF corporation)
[0364] The structure of DMG-PEG2000 (also labeled as DMG-PEG) is shown below.
[0365] [Chemical formula 29]
[0366]
[0367] 5 mg of PTEN aSO was dissolved in 1 mL of sterile water, and diluted with a 10 mmol / L acetic acid buffer at pH 4 to obtain an aqueous phase with a nucleic acid concentration of 54.6 μmol / L. Subsequently, a syringe pump was used to mix the aqueous phase and the oil phase with a micro mixer (refer to Japanese Patent No. 5288254) so that the volume ratio of the aqueous phase to the oil phase was aqueous phase: oil phase = 3:1, and the mixed solution was diluted 2 times with phosphate buffered saline (PBS) to obtain a dispersion of nucleic acid lipid particles.
[0368] <Measurement of particle size>
[0369] The lipid particle dispersion was diluted 5-fold with phosphate buffered saline (PBS) using Zeta potential particle size measurement system ELS-Z2 (Otsuka Electronics Co., Ltd.) to measure the particle size and polydispersity index of the lipid particles.
[0370] <Evaluation of PTEN aSO content>
[0371] (Total nucleic acid concentration quantification)
[0372] To 60 μL of lipid particles retaining nucleic acid, 30 μL of 3 mol / L sodium acetate aqueous solution and 9 μL of glycogen were added, followed by 1.5 mL of ethanol to dissolve lipids and precipitate nucleic acid only. Then, centrifugation was performed to remove the supernatant. After air drying for more than 15 minutes, water was added to redissolve it, and the concentration was measured using Nanodrop ND1000 (Thermo Fisher Scientific), thereby quantifying the total nucleic acid concentration.
[0373] (Quantification of nucleic acid concentration in the external aqueous phase)
[0374] Quantification was performed using the Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher Scientific) according to the protocol. First, the 20×TE buffer contained in the above kit was diluted with water to make 1×TE buffer. In addition, TE stands for Tris / EDTA (ethylenediaminetetraacetic acid). In order to quantify only the nucleic acid in the external aqueous phase, the lipid particle dispersion containing the nucleic acid was diluted 50 times with 1×TE buffer.
[0375] 100 μL of lipid particle dispersion diluted 10,000 times was placed in a 96-well plate, and then 100 μL of RiboGreen reagent (the reagent included in the above-mentioned Quanti-iT Ribogreen RNAAssay Kit) diluted 2,000 times with 1×TE buffer was added to the sample, and the nucleic acid concentration in the external aqueous phase was quantified by measuring fluorescence (excitation wavelength: 485 nm, fluorescence wavelength: 535 nm) using an ELISA reader Infinite F200 (TECAN).
[0376] (Calculation of internal content)
[0377] Using the quantitative results of the total nucleic acid concentration and the nucleic acid concentration in the external aqueous phase obtained in the above steps, the nucleic acid content of the nucleic acid lipid particles was calculated according to the following formula.
[0378] Nucleic acid content (%) = (total nucleic acid concentration - nucleic acid concentration in the external aqueous phase) / total nucleic acid concentration × 100. The calculation results are shown in Table 1.
[0379] [Table 1]
[0380]
[0381] <In vitro evaluation of PTEN mRNA reduction>
[0382] (Cells used for evaluation)
[0383] In an in vitro experiment using a431 cells (American Type Culture Collection), a mixture of E-MEM (gibco), FBS (fetal bovine serum) (gibco), Penicillin-streptomycin (gibco), and NEaa (Non-Essential aminoacid) (FUJIFILM WakoPure Chemical Corporation) in a ratio of 88:10:1:1 was used as a culture medium.
[0384] (Quantification of PTEN mRNA by PCR)
[0385] PTEN protein mRNA assay was performed using the TaqMan(registered trademark) Fast advanced Cells-to-CT TM Kit (Thermo Fisher Scientific). A431 cells were added with a dispersion of nucleic acid lipid particles, Naked aSO or PBS to a final concentration of 500 nmol / L as aSO concentration. The cells were incubated at 37°C and 5% CO 2 After 24 hours of exposure to the control, the culture supernatant was removed and the cells were washed once with PBS at 4°C. After removing the PBS, 50 μL / well of Lysis solution was added and the cells were left to stand at room temperature for 5 minutes to obtain cell lysates. The cell lysates were analyzed using TaqMan (registered trademark) Fastvanced Cells-to-CT TM Reverse transcription and PCR reactions were carried out using Kit (Thermo Fisher scientific), Hs02621230_s1, FaM / MGB (Thermo Fisher scientific), Human GaPDH Endogenous Control, and VIC (registered trademark) / MGB (Thermo Fisher scientific) as PCR reaction reagents.
[0386] The PTEN mRNA value of each sample was calculated by the ΔΔCt method. Specifically, the ΔCt value of each sample was calculated by subtracting the Ct value of GaPDH from the Ct value of PTEN. The ddCt value was calculated by subtracting the average value of the ΔCt value of the PBS treatment group from the calculated ΔCt value. Based on each ΔΔCt value, the PTEN mRNA expression ratio was calculated. The results are shown in Table 2.
[0387] [Table 2]
[0388] PTEN mRNA expression ratio in A431 cells relative to the control
[0389] A431 cells Lipid composition 1 0.09 Lipid composition 2 0.27 Lipid composition 5 0.58 Lipid composition 7 0.2 Lipid composition 8 0.21 Comparative lipid composition 1 0.66
[0390] <Preparation of Nucleic Acid Lipid Particles>
[0391] Compound A (the lipid represented by formula [Chemical Formula 28] of the present application), DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine (product name: COATSOME(R) MC-8080; manufactured by NOF Corporation), the compound listed in Table 3, and DMG-PEG2000 (1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 product name: SUNBRIGHT(R) GM-020; manufactured by NOF Corporation) were dissolved in ethanol at a molar ratio of 50:10:38.5:1.5 until the total lipid concentration reached 12.5 mmol / L, thereby obtaining an oil phase.
[0392] FLuc mRNA (product name: CleanCap FLuc mRNA; manufactured by TriLink) was diluted with a 50mmol / L citric acid buffer at pH 4 in such a way that the weight ratio of the total lipid concentration after mixing the oil phase and the water phase to the mRNA concentration was 20:1 to obtain an aqueous phase. Subsequently, the aqueous phase and the oil phase were mixed using a NanoAssemblr (Precision NanoSystems) in such a way that the volume ratio of the aqueous phase to the oil phase was aqueous phase: oil phase = 3:1, and the mixed solution was diluted 2 times with phosphate buffered saline (PBS) to obtain a dispersion of mRNA lipid particles. The dispersion was dialyzed against 20mMTris buffer pH 7.4 containing 8% sucrose using a dialysis kit (Slide-A-Lyzer G2, MWCO: 10kD, Thermo Fisher Scientific) to remove ethanol and obtain FLuc mRNA-containing lipid particles.
[0393] <Measurement of particle size>
[0394] The particle size of the mRNA-containing lipid particles was measured by using a Zeta potential and particle size measurement system NanoSAQLA (Otsuka Electronics Co., Ltd.) after the lipid particles were diluted 5-fold with phosphate-buffered saline (PBS).
[0395] <Evaluation of mRNA inclusion rate>
[0396] (Total mRNA concentration quantification)
[0397] FLuc mRNA was diluted with MilliQ water to prepare a two-fold dilution series of samples ranging from 100 μg / mL to 3.1 μg / mL, and a calibration curve solution was prepared. 50 μL of the calibration curve solution or mRNA lipid nanoparticles was mixed with 450 μL of methanol to prepare a measurement solution.
[0398] The absorbance of each assay solution at 260 nm and 330 nm was measured using a UV plate reader (Multiskan Go, Thermo fisher scientific), and the absorbance at 330 nm was subtracted from the absorbance at 260 nm to obtain the absorbance of each assay solution. The total aqueous phase mRNA concentration was calculated based on the calibration curve using the absorbance of each sample assay solution.
[0399] (Quantification of mRNA concentration in the external aqueous phase)
[0400] The concentration of nucleic acid in the external aqueous phase was quantified by the standard addition method using the Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher Scientific). First, the 20×TE buffer contained in the above kit was diluted with water to make it into 1×TE buffer. In addition, TE stands for Tris / EDTA (ethylenediaminetetraacetic acid). FLuc mRNA was diluted with TE buffer until the final concentration was 0-400 ng / mL, and a nucleic acid dilution series was prepared. After 10 μL of mRNA lipid nanoparticles diluted 5 times with TE buffer and 90 μL of the nucleic acid dilution series were mixed in a 96-well plate, 100 μL of RiboGreen reagent diluted 200 times with TE buffer was added to each well, and fluorescence was measured using a fluorescence plate reader (Infitite 200Pro M nano+, TECAN) (excitation wavelength: 485 nm, fluorescence wavelength: 535 nm). Based on the results obtained and according to the standard addition method, the concentration of mRNA in the external aqueous phase of each assay solution was calculated.
[0401] (Calculation of internal content)
[0402] The mRNA internalization rate of the mRNA lipid nanoparticles was calculated according to the following formula using the quantitative results of the total mRNA concentration and the mRNA concentration in the external aqueous phase obtained in the above steps.
[0403] mRNA content rate (%) = (total mRNA concentration - mRNA concentration in the external water phase) ÷ total mRNA concentration × 100
[0404] The results are shown in Table 3.
[0405] [Table 3]
[0406] Example Compound No. Particle size (nm) Nucleic acid content (%) Comparative lipid composition 2 Comparative Compound 1 28 83.5 Lipid composition 11 Compound 2 155 66.6 Lipid composition 12 Compound 3 151 64.5 Lipid composition 13 Compound 4 147 66.6 Lipid composition 14 Compound 5 171 58.9 Lipid composition 15 Compound 6 145 58.0 Lipid composition 16 Compound 7 150 68.3 Lipid composition 17 Compound 8 146 73.5 Lipid composition 18 Compound 10 128 63.3 Lipid composition 19 Compound 11 135 69.5
[0407] <In vitro Luciferase expression assay>
[0408] In vitro luciferase expression assay was performed.
[0409] (Cells used for evaluation)
[0410] In an in vitro experiment using Hela cells, a mixture of E-MEM (gibco), FBS (fetal bovine serum) (gibco), Penicillin-streptomycin (gibco), and NEaa (Non-Essential amino acid) (FUJIFILM Wako Pure Chemical Corporation) at a ratio of 88:10:1:1 was used as a culture medium.
[0411] (Quantification of Luciferase expression)
[0412] The luciferase expression level was determined according to the protocol of ONE-Glo Luciferase Assay System (Promega). A dispersion of nucleic acid lipid particles prepared in such a way that the final concentration was 80 ng / well and pre-cultured with hApoE (FUJIFILM Wako Pure Chemical Corporation) was added to Hela cells. The cells were incubated at 37°C and 5% CO. 2 After exposure to the control for 24 hours, a mixture of Luciferase Assay Buffer and Luciferase Assay Substrate was added at 100 μL / well and allowed to stand at room temperature for 3 minutes to obtain an assay solution. The assay solution was pipetted into another plate at 50 μL each time, and the luminescence was measured using a plate reader (Envision, Perkin Elmer). The results are shown in Table 4.
[0413] [Table 4]
[0414]
[0415] It was found that the nucleic acid-lipid composition of the present invention can confirm good Luciferase expression and has excellent mRNA delivery ability compared to the nucleic acid-lipid composition of the comparative example.
Claims
1. A compound represented by formula (1), [Chemical formula 1] In the formula, [Chemical formula 2] represents a single bond or a double bond, R 201 represents a cyclic hydrocarbon group which may be substituted with one or more substituents, wherein the substituents are hydrocarbon groups having 1 to 18 carbon atoms, R 102 express (i) Hydrogen atoms, (ii) may be selected from OH, SH, COOH, NR 106 R 107 、N(R 108 )C(O)R 109 or a hydrocarbon group having 1 to 4 carbon atoms substituted with one or more substituents in CF3, (iii)C(O)R 103 or (iv)C(O)NR 104 R 105 , R 103 Indicates that it can be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or a hydrocarbon group having 1 to 4 carbon atoms substituted by one or more substituents in CF3, R 104 and R 105 Each independently represents a hydrogen atom, or may be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or a hydrocarbon group having 1 to 4 carbon atoms substituted by one or more substituents in CF3, R 106 , R 107 , R 108 and R 109 Each independently represents a hydrogen atom, or may be selected from OH, SH, COOH, NR 110 R 111 、N(R 112 )C(O)R 113 or a hydrocarbon group having 1 to 4 carbon atoms substituted by one or more substituents in CF3, R 110 , R 111 , R 112 and R 113 Each independently represents a hydrogen atom or a hydrocarbon group having 1 to 4 carbon atoms which may be substituted with one or more substituents selected from OH and SH.
2. The compound according to claim 1, wherein R 102 express (i) Hydrogen atom or (iv)C(O)NR 104 R 105 。 3. The compound according to claim 1 or 2, which is a compound represented by formula (1A), [Chemical formula 3] In the formula, R 201 As claimed in claim 1.
4. The compound according to any one of claims 1 to 3, wherein The cyclic hydrocarbon group is an aliphatic cyclic hydrocarbon group.
5. The compound according to claim 4, wherein The aliphatic cyclic hydrocarbon group is a monocyclic hydrocarbon group.
6. The compound according to claim 5, wherein The monocyclic hydrocarbon group has 3 to 18 carbon atoms.
7. The compound according to claim 4, wherein The aliphatic cyclic hydrocarbon group is a bicyclic hydrocarbon group.
8. The compound according to claim 7, wherein The bicyclic hydrocarbon group has 4 to 18 carbon atoms.
9. The compound according to claim 4, wherein The aliphatic cyclic hydrocarbon group is a tricyclic hydrocarbon group.
10. The compound according to claim 9, wherein The tricyclic hydrocarbon group has 5 to 18 carbon atoms.
11. The compound according to any one of claims 1 to 3, wherein The cyclic hydrocarbon group is an aromatic hydrocarbon group.
12. The compound according to claim 11, wherein The aromatic hydrocarbon group has 6 to 10 carbon atoms.
13. The compound according to any one of claims 1 to 12, wherein R 201 The substituent on the cyclic hydrocarbon group in the definition of is a hydrocarbon group having 1 to 18 carbon atoms.
14. A compound according to any one of claims 1 to 13, wherein R 201 The substituent on the cyclic hydrocarbon group in the definition of is a hydrocarbon group having 1 to 8 carbon atoms.
15. A lipid composition comprising the compound according to any one of claims 1 to 14 and at least one lipid.
16. The lipid composition of claim 15, further comprising a nucleic acid.
17. The lipid composition according to claim 15 or 16, further comprising a pharmaceutically acceptable carrier.
18. The lipid composition according to any one of claims 15 to 17, which is a composition for introducing a nucleic acid into a cell.
19. The lipid composition according to any one of claims 15 to 17, which is a composition for in vivo nucleic acid delivery.
20. The lipid composition according to any one of claims 15 to 19, which is a lipid particle.
Citation Information
Cited By
Cholesterol derivative as well as preparation method and application thereof
CN121758535A
